Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective randomized multicenter study of chemotherapy in cervical carcinoma
2017-003221-15Phase 3Terminated
- Sponsor
- University of Cologne
- Start
- Oct 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in cervical squamous cell carcinoma (CSCC) comparing Carboplatin + paclitaxel with Cisplatin + ifosfamide (2 arms). Primary endpoint: Disease Free Survival (DFS). Started Oct 2018; status: terminated.
02
Drugs
carboplatinpaclitaxelcisplatinifosfamide
03
Conditions
cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on 2017-003221-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003221-15.